



**RPG LIFE SCIENCES LIMITED**

Regd. Off.: RPG House  
463, Dr. Annie Besant Road  
Worli, Mumbai 400030, India  
Tel: +91-22-24981650 / 66606375  
Fax: +91-22-24970127  
Email: info@rpglifesciences.com  
www.rpglifesciences.com  
CIN : L24232MH2007PLC169354

May 06, 2026

**National Stock Exchange of India Limited**

Plot No. C/1, "G" Block, Exchange Plaza,  
Bandra Kurla Complex, Bandra (East),  
Mumbai 400 051

**Symbol: RPGLIFE**

Dear Sirs /Madam,

**Sub: Financial Results for the quarter and year ended March 31, 2026 in machine-readable and searchable form.**

This is with reference to your email dated May 05, 2026, we understand that some of the contents of the Financial Results of the Company for the quarter and year ended March 31, 2026, submitted on April 29, 2026 are not in machine-readable and searchable form.

As desired, we are once again submitting the Machine Readable / legible copy / Searchable Form of Financial Results of the Company for the quarter and year ended March 31, 2026.

Please note that there are no changes in the Financial Results filed by the Company on April 29, 2026.

This is for your information and records.

Thanking you,

Yours Sincerely,  
For RPG Life Sciences Limited

Rajesh Shirambekar  
Head- Legal & Company Secretary

Encl: as above



April 29, 2026

**RPG LIFE SCIENCES LIMITED**  
Regd. Off.: RPG House  
463, Dr. Annie Besant Road  
Worli, Mumbai 400030, India  
Tel: +91-22-24981650 / 66606375  
Fax: +91-22-24970127  
Email: info@rpglifesciences.com  
www.rpglifesciences.com  
CIN : L24232MH2007PLC169354

**National Stock Exchange of India Limited**

Plot No. C/1, "G" Block, Exchange Plaza,  
Bandra Kurla Complex, Bandra (East),  
Mumbai 400 051

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 001

**Symbol: RPGLIFE**

**Security Code: 532983**

Dear Sirs /Madam,

**Sub: Outcome of the Board Meeting held on April 29, 2026**

Pursuant to the provisions of Regulations 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and such other rules and regulations, if and as may be applicable, this is to inform that the Board of Directors ('Board') of the Company at its meeting held today, which commenced at 03:00 PM (IST) and concluded at 6:30 PM (IST), *inter-alia*, unanimously approved/ consented to/took on record, the following:

**1. Audited Financial Results**

Audited Financial Results and Statements (Standalone and Consolidated) of the Company, for the quarter and year ended March 31, 2026, together with the Statutory Auditor's Report(s) and a declaration duly signed by the Chief Financial Officer stating that the said Audit Reports are with an unmodified opinion.

**2. Dividend**

Recommendation of Dividend of Rs.24/- (Rupees Twenty Four only), i.e.300% per equity share of face value of Rs. 8/- (Rupees Eight only) each fully paid up, for FY 2025-26, subject to approval of shareholders at the ensuing Annual General Meeting, which will be paid / dispatched within 30 days of such approval.

**3. Appointment of Additional Non-Executive Independent Director**

Dr. Pratit Samdani (DIN: 10139232) was appointed, pursuant to the recommendation of the Nomination and Remuneration Committee, as an Additional Non-Executive Independent Director for a period of 5 (five) years from April 29, 2026, to April 28, 2031, not liable to retire by rotation subject to approval of the shareholders.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed herewith as Annexure - A



**RPG LIFE SCIENCES LIMITED**

Regd. Off.: RPG House  
463, Dr. Annie Besant Road  
Worli, Mumbai 400030, India  
Tel: +91-22-24981650 / 66606375  
Fax: +91-22-24970127  
Email: info@rpglifesciences.com  
www.rpglifesciences.com  
CIN : L24232MH2007PLC169354

**4. Amendment to the Code**

Amendment to the Code of fair disclosure, internal procedures and conduct for regulating, monitoring and reporting of trading by designated persons and immediate relatives of designated persons including policy on determination of legitimate purpose ("the Code"). The updated code is available on <https://www.rpglifesciences.com/>

Ensuing Annual General Meeting of the Company shall be convened and held as per the directives and circulars issued by the relevant authorities and the details thereof shall be intimated separately.

Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, and the underlying Code of the Company and other applicable rules and regulations, the Trading Window for dealing in securities of the Company, shall open post 48 hours after declaration of aforesaid results.

This is for your information and record.

Thanking you,

Yours Sincerely,  
For RPG Life Sciences Limited

Rajesh Shirambekar  
Head- Legal & Company Secretary

Encl: as above

**(Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)**

**Annexure - A**

**Appointment of Dr. Pratit Samdani (DIN: 10139232) as an Additional Non-Executive Independent Director:**

1	Reason for Change viz. appointment, <del>reappointment, resignation, removal, death or otherwise</del>	Appointment of Dr. Pratit Samdani as Additional Non-Executive Independent Director.
2	Date of Appointment/ <del>reappointment /cessation (as applicable) /reappointment/ term of appointment</del>	April 29, 2026
3	Brief Profile (in case of appointment)	<p>Dr. Pratit Samdani is one of Mumbai's most respected and accomplished physicians, with over two decades of excellence in Internal Medicine and Critical Care. Rated as Mumbai's Top Physician since 2010, he is widely recognized for his clinical expertise, academic leadership, and pioneering contributions to research in Diabetes, Hypertension, Infectious Diseases, and Intensive Care Medicine. with a distinguished academic background — including a Gold Medal in F.C.P.S. (Medicine) and securing Second Rank in M.D. (Internal Medicine) from Bombay University. He combines deep scientific knowledge with compassionate, patient-centered care.</p> <p>Dr. Samdani has also contributed in field of Research &amp; Academic, including studies on Diabetes &amp; Hypertension, Lipid management, Pneumococcal vaccination and Infectious diseases. Dr. Samdani has been Chief Investigator and Principal Investigator for numerous national and international multicentric clinical trials. He has published in reputed medical journals including the British Medical Journal (BMJ) and JAMA India.</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	Dr. Samdani is not related to any Director or Key Managerial Personnel of the Company.
5	Affirmation	As per declaration submitted to the Company, Dr. Pratit Samdani has confirmed that he is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

**Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To  
The Board of Directors of  
RPG Life Sciences Limited

**Report on the audit of the Standalone Financial Results****Opinion**

We have audited the accompanying statement of quarterly and year to date standalone financial results of RPG Life Sciences Limited (the "Company") for the quarter ended March 31, 2026 and for the year ended March 31, 2026 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2026 and for the year ended March 31, 2026.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Standalone Financial Results**

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.



# **S R B C & CO LLP**

**Chartered Accountants**

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



# **SRBC & CO LLP**

**Chartered Accountants**

## **Other Matter**

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

**For SRBC & CO LLP**

Chartered Accountants

**ICAI Firm Registration Number: 324982E/E300003**

*Aruna*

**per Aruna Kumaraswamy**

Partner

Membership No.: 219350

UDIN: 26219350RJZAZN1814


Place: Mumbai

Date: April 29, 2026



**STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026**

Particulars	(Rs. in Lakhs)				
	Quarter ended			Year ended	
	31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
	Audited	Unaudited	Audited	Audited	Audited
1 Revenue from Operations	17,689	18,003	14,309	70,752	65,343
2 Other Income (Refer note 3(a))	1,236	341	506	2,554	1,268
<b>3 Total Income (1+2)</b>	<b>18,925</b>	<b>18,344</b>	<b>14,815</b>	<b>73,306</b>	<b>66,611</b>
<b>4 Expenses</b>					
(a) Cost of Materials Consumed	3,643	3,479	2,689	13,598	11,026
(b) Purchases of Stock-in-Trade	2,263	4,363	2,122	13,810	9,514
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	153	(1,352)	61	(2,199)	861
(d) Employee Benefits Expense	3,630	3,532	3,160	14,148	12,614
(e) Finance Costs	39	25	18	89	62
(f) Depreciation and Amortisation Expense	574	538	537	2,148	2,143
(g) Other Expenses	4,713	4,005	3,728	16,682	15,363
<b>Total Expenses</b>	<b>15,015</b>	<b>14,590</b>	<b>12,315</b>	<b>58,276</b>	<b>51,583</b>
<b>5 Profit before exceptional items and tax (3-4)</b>	<b>3,910</b>	<b>3,754</b>	<b>2,500</b>	<b>15,030</b>	<b>15,028</b>
6 Exceptional items (net) (Refer Note 3)	110	(842)	10,990	390	8,260
<b>7 Profit before tax</b>	<b>4,020</b>	<b>2,912</b>	<b>13,490</b>	<b>15,420</b>	<b>23,288</b>
<b>8 Income tax expenses</b>					
a. Current Tax	721	691	1,748	3,475	4,969
b. Deferred Tax	309	8	7	428	(5)
<b>Total tax expenses</b>	<b>1,030</b>	<b>699</b>	<b>1,755</b>	<b>3,903</b>	<b>4,964</b>
<b>9 Profit for the period (7-8)</b>	<b>2,990</b>	<b>2,213</b>	<b>11,735</b>	<b>11,517</b>	<b>18,324</b>
<b>10 Other Comprehensive Income</b>					
(i) Items that will not be reclassified to Profit or Loss	10	(91)	(154)	(86)	(147)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	(2)	23	39	22	37
<b>Other Comprehensive Income / (Loss) Net of Tax</b>	<b>8</b>	<b>(68)</b>	<b>(115)</b>	<b>(64)</b>	<b>(110)</b>
<b>11 Total Comprehensive Income for the period (9+10)</b>	<b>2,998</b>	<b>2,145</b>	<b>11,620</b>	<b>11,453</b>	<b>18,214</b>
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323
13 Other Equity				59,214	51,730
14 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):					
(a) Basic (in Rs.)	18.08	13.38	70.96	69.64	110.80
(b) Diluted (in Rs.)	18.08	13.38	70.96	69.64	110.80

**SIGNED FOR IDENTIFICATION  
BY**  
  
**SRBC & CO LLP**  
MUMBAI



**Standalone Statement of Assets and Liabilities**

(Rs. in Lakhs)

Particulars	As at March 31, 2026	As at March 31, 2025
	(Audited)	(Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment (Including Right of use assets)	19,170	16,118
Capital work-in-progress	2,002	395
Other intangible assets	484	1,065
Intangible assets under development (Net)	327	1,211
Financial assets		
i. Investments	3,579	101
ii. Loans	14	17
iii. Other financial assets	43	43
Current Tax asset (Net)	526	156
Deferred tax assets (Net)	-	100
Other non-current assets	700	50
<b>Total non-current assets</b>	<b>26,845</b>	<b>19,256</b>
<b>Current assets</b>		
Inventories	12,384	9,298
Financial assets		
i. Investments	8,390	12,590
ii. Trade receivables	11,668	8,676
iii. Cash and cash equivalents	11,568	2,870
iv. Bank balances other than (iii) above	4,110	11,091
v. Other financial assets	929	579
Other current assets	3,420	1,421
<b>Total current assets</b>	<b>52,469</b>	<b>46,525</b>
<b>Total assets</b>	<b>79,314</b>	<b>65,781</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	1,323	1,323
Other equity	59,214	51,730
<b>Total equity</b>	<b>60,537</b>	<b>53,053</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
i. Borrowings	1,333	-
ii. Other financial liabilities	344	291
Provisions	741	454
Deferred tax liabilities (Net)	306	-
<b>Total non-current liabilities</b>	<b>2,724</b>	<b>745</b>
<b>Current liabilities</b>		
Financial liabilities		
i. Borrowings	667	-
ii. Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	510	366
(b) total outstanding dues of creditors other than micro enterprises and small enterprises	9,211	7,573
iii. Other financial liabilities	2,044	1,763
Other current liabilities	586	670
Provisions	2,911	1,611
Current tax liabilities (Net)	124	-
<b>Total current liabilities</b>	<b>16,053</b>	<b>11,983</b>
<b>Total liabilities</b>	<b>18,777</b>	<b>12,728</b>
<b>Total equity and liabilities</b>	<b>79,314</b>	<b>65,781</b>

**SIGNED FOR IDENTIFICATION  
BY**  
  
**S R B C & CO LLP  
MUMBAI**



Standalone Audited Statement of Cash flows for the year ended March 31, 2026

(Rs. in Lakhs)

	Particulars	For the year ended	For the year ended
		March 31, 2026	March 31, 2025
		Audited	Audited
<b>A</b>	<b>Cash Flow from operating activities</b>		
	Profit before income tax	15,420	23,288
	Adjustments for		
	Add/(Less) :		
	Depreciation and amortisation expenses	2,148	2,143
	Net impact of Insurance claim on loss arising on account of fire incident	(2,475)	1,633
	Insurance claim received for loss of profit	(791)	-
	Finance costs	89	62
	Profit on assignment of surplus leasehold land along with built-up structures	-	(10,018)
	Profit on disposal of property, plant and equipment	(1)	(120)
	Unrealised exchange rate difference	(61)	(28)
	Provision for doubtful debts and advances (Net)	75	(162)
	Impairment of Intangible Assets Under Development	916	-
	Interest income	(967)	(321)
	Gain on sale of investments	(345)	(221)
	Provisions no longer required and written back	(20)	(115)
	Net fair value gain on financial assets mandatorily measured at fair value through profit or loss	(299)	(475)
		<b>13,689</b>	<b>15,666</b>
	<b>Working capital adjustments:</b>		
	(Increase) in trade receivables	(2,963)	(3,575)
	Decrease in financial assets - Loans	3	2
	(Increase) / Decrease in other financial assets	401	(76)
	(Increase) / Decrease in other current assets	(1,999)	610
	(Increase) / Decrease in inventories	(3,086)	619
	Increase / (Decrease) in trade payables	1,759	954
	Increase / (Decrease) in other financial liabilities	151	(1,585)
	Increase / (Decrease) in provisions	1,500	299
	Increase / (Decrease) in other current liabilities	(84)	147
	<b>Cash generated from operations</b>	<b>9,371</b>	<b>13,061</b>
	Income taxes paid	(3,721)	(5,275)
	<b>Net cash inflow from operating activities</b>	<b>5,650</b>	<b>7,786</b>
<b>B</b>	<b>Cash flow from investing activities</b>		
	Acquisition of property, plant and equipment, CWIP and Intangible assets	(6,536)	(3,603)
	Proceeds from sale of property, plant and equipment	-	10,947
	Interim payment received from insurance claim	2,327	450
	Movement in Other bank balances (Net)	6,981	(9,416)
	Investment in Mutual Funds	(1,000)	(7,650)
	Investment in equity shares of wholly owned subsidiary	(3,478)	-
	Proceeds from Sale of Mutual funds	5,845	4,771
	Interest received	967	321
	<b>Net cash inflow/(outflow) from investing activities</b>	<b>5,106</b>	<b>(4,180)</b>
<b>C</b>	<b>Cash flow from financing activities</b>		
	Interest paid	(89)	(62)
	Proceeds from Long Term Borrowings	2,000	-
	Dividend paid	(3,969)	(2,646)
	<b>Net cash (outflow) from financing activities</b>	<b>(2,058)</b>	<b>(2,708)</b>
	<b>Net increase in cash and cash equivalents</b>	<b>8,698</b>	<b>898</b>
	Add: Cash and cash equivalents at the beginning of the year	2,870	1,972
	<b>Cash and cash equivalents at the end of the year</b>	<b>11,568</b>	<b>2,870</b>

**SIGNED FOR IDENTIFICATION**  
BY *AK*  
**S R B C & CO LLP**  
**MUMBAI**




**Notes:**


- The above audited consolidated financial results of the Group have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meeting held on April 29, 2026.
- The Group operates in only one reportable business segment i.e. Pharmaceuticals.
- Exceptional items:

Exceptional Income / (Expenses)	Quarter ended			Year ended	
	31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
	Audited	Unaudited	Audited	Audited	Audited
Profit on assignment of surplus vacant leasehold land along with built-up structures situated at MIDC, Navi Mumbai	-	-	12,623	-	9,893
Net impact of Insurance claim on loss arising on account of fire incident - Refer note 3(a)	1,087	266	(1,633)	2,475	(1,633)
Impact of New Labour Codes - Refer note 3(b)	(61)	(1,108)	-	(1,169)	-
Impairment of Intangible Assets Under Development (IAUD) - Refer note 3(c)	(916)	-	-	(916)	-
<b>Total exceptional items - Income / (Expenses)</b>	<b>110</b>	<b>(842)</b>	<b>10,990</b>	<b>390</b>	<b>8,260</b>

- 3(a) During the previous year, a fire incident occurred at one of the manufacturing blocks of the Group's API plant located in Navi Mumbai. Following the incident, the Group carried out a comprehensive assessment of the losses incurred and accordingly submitted an insurance claim based on the estimated loss. Based on the final assessment and estimated costs, the Group had recognised a cumulative loss of Rs 2,295 lakhs up to the period ended December 31, 2025. During the quarter ended March 31, 2026, the insurance company acknowledged the claim amount of Rs 3,137 lakhs as full and final settlement of the claim. The Group had received Rs 2,050 lakhs in multiple tranches up to December 31, 2025. The balance amount of Rs 1,087 lakhs was received in two tranches, comprising Rs 652 lakhs during the quarter ended March 31, 2026 and Rs 435 lakhs in April 2026. Accordingly, after offsetting the insurance proceeds received during the year against the loss recognised on account of the fire incident, the Group has recognised a net income of Rs 2,475 lakhs for the year and disclosed the same as an Exceptional item. In addition, during the quarter ended March 31, 2026, the Group received the final settlement of Rs 791 lakhs towards compensation for loss of profit arising from business interruption due to the fire incident. The same has been recognised under Other Income for the said quarter.
- 3(b) On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Group has assessed and disclosed the incremental impact of these changes on the basis of the best information available and guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group has presented such incremental impact as "Impact of New Labour Codes" under "Exceptional Items" in the consolidated statement of profit and loss for the year ended March 31, 2026. The incremental impact on provisions for employee benefits expenses of Rs. 1,169 lakhs (Rs. 61 lakhs for the quarter ended March 31, 2026 and Rs. 1,108 for the period ended December 31, 2025) primarily arises due to change in wage definition. The Group continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect as and when such clarifications are issued/rules are notified.
- 3(c) Exceptional items for the year ended March 31, 2026 relates to write off of an intangible asset under development. The Group does not expect any future economic benefits to flow to the Group hence the cost incurred till date have been charged off during the quarter.
- The Board of Directors of the Company, at its meeting held on December 15, 2025, approved the transfer of the API division ("the Division") of the Company, to its wholly owned subsidiary (WOS) viz, RPG Active Pharma Limited, which was incorporated on December 24, 2025, subject to receipt of all requisite consents. The Group expects the transaction to be concluded upon receipt of the requisite approvals and completion of customary conditions precedent.
- Figures of the quarter ended March 31, 2026 and March 31, 2025 are the balancing figure between audited figures in respect of the full financial year and the year to date figures upto the third quarter of the relevant financial year which were subjected to limited review by Auditors.
- The Board of Directors has recommended a final dividend of Rs. 24 (Rupees Twenty four only) per equity share (300% on the face value of Rs 8 each), subject to the approval of shareholders at the ensuing Annual General Meeting

Place: Mumbai  
Date: April 29, 2026

**SIGNED FOR IDENTIFICATION  
BY**  
  
**S R B C & CO LLP  
MUMBAI**

For RPG Life Sciences Limited  
  
Ashok Nair  
Managing Director  
DIN: 07906710



**Independent Auditor's Report on the Quarterly and Year to Date Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To  
The Board of Directors of  
RPG Life Sciences Limited

**Report on the audit of the Consolidated Financial Results****Opinion**

We have audited the accompanying statement of quarterly and year to date consolidated financial results of RPG Life Sciences Limited ("Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended March 31, 2026 and for the year ended March 31, 2026 ("Statement"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. includes the results of the following entity;

Nature of Relationship	Name of the Entity
Subsidiary	RPG Active Pharma Limited

- ii. are presented in accordance with the requirements of the Listing Regulations in this regard; and  
iii. gives a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information of the Group for the quarter ended March 31, 2026 and for the year ended March 31, 2026.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Consolidated Financial Results**

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of their respective companies and for preventing and detecting frauds and other irregularities; selection and application of appropriate



accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of their respective companies to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of their respective companies.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.



# **S R B C & CO LLP**

Chartered Accountants

- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group of which we are the independent auditors and whose financial information we have audited, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the Master Circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.


## **Other Matter**

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the end of the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

**For S R B C & CO LLP**

Chartered Accountants

**ICAI Firm Registration Number: 324982E/E300003**



**per Aruna Kumaraswamy**  
Partner

Membership No.: 219350

UDIN: 26219350VBPCPG3401

Place: Mumbai

Date: April 29, 2026




Consolidated Audited Statement of Cash flows for the year ended March 31, 2026

(Rs. in Lakhs)

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
	Audited	Audited
<b>A Cash Flow from operating activities</b>		
Profit before income tax	15,420	23,288
Adjustments for		
Add/(Less) :		
Depreciation and amortisation expenses	2,148	2,143
Net impact of Insurance claim on loss arising on account of fire incident	(2,475)	1,633
Insurance claim received for loss of profit	(791)	-
Finance costs	89	62
Profit on assignment of surplus leasehold land along with built-up structures	-	(10,018)
Profit on disposal of property, plant and equipment	(1)	(120)
Unrealised exchange rate difference	(61)	(28)
Provision for doubtful debts and advances (Net)	75	(162)
Impairment of Intangible Assets Under Development	916	-
Interest income	(967)	(321)
Gain on sale of investments	(345)	(221)
Provisions no longer required and written back	(20)	(115)
Net fair value gain on financial assets mandatorily measured at fair value through profit or loss	(299)	(475)
	<b>13,689</b>	<b>15,666</b>
<b>Working capital adjustments:</b>		
(Increase) in trade receivables	(2,963)	(3,575)
Decrease in financial assets - Loans	3	2
(Increase) / Decrease in other financial assets	400	(76)
(Increase) / Decrease in other current assets	(1,999)	610
(Increase) / Decrease in inventories	(3,086)	619
Increase / (Decrease) in trade payables	1,761	954
Increase / (Decrease) in other financial liabilities	151	(1,585)
Increase / (Decrease) in provisions	1,500	299
Increase / (Decrease) in other current liabilities	(84)	147
<b>Cash generated from operations</b>	<b>9,372</b>	<b>13,061</b>
Income taxes paid	(3,722)	(5,275)
<b>Net cash inflow from operating activities</b>	<b>5,650</b>	<b>7,786</b>
<b>B Cash flow from investing activities</b>		
Acquisition of property, plant and equipment, CWIP and Intangible assets	(6,536)	(3,603)
Proceeds from sale of property, plant and equipment	-	10,947
Interim payment received from insurance claim	2,327	450
Movement in Other bank balances (Net)	6,981	(9,416)
Investment in Mutual Funds	(1,000)	(7,650)
Proceeds from Sale of Mutual fund	5,845	4,771
Interest received	967	321
<b>Net cash inflow/(outflow) from investing activities</b>	<b>8,584</b>	<b>(4,180)</b>
<b>C Cash flow from financing activities</b>		
Interest paid	(89)	(62)
Proceeds from Long Term Borrowings	2,000	-
Dividend paid	(3,969)	(2,646)
<b>Net cash (outflow) from financing activities</b>	<b>(2,058)</b>	<b>(2,708)</b>
<b>Net increase in cash and cash equivalents</b>	<b>12,176</b>	<b>898</b>
Add: Cash and cash equivalents at the beginning of the year	2,870	1,972
<b>Cash and cash equivalents at the end of the year</b>	<b>15,046</b>	<b>2,870</b>


**SIGNED FOR IDENTIFICATION  
BY**  
  
**SRBC & CO LLP  
MUMBAI**



**Consolidated Statement of Assets and Liabilities**

(Rs. in Lakhs)

Particulars	As at March 31, 2026	As at March 31, 2025
	(Audited)	(Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment (Including Right of use assets)	19,170	16,118
Capital work-in-progress	2,002	395
Other intangible assets	484	1,065
Intangible assets under development (Net)	327	1,211
Financial assets		
i. Investments	101	101
ii. Loans	14	17
iii. Other financial assets	43	43
Current Tax asset (Net)	527	156
Deferred tax assets (Net)	-	100
Other non-current assets	700	50
<b>Total non-current assets</b>	<b>23,368</b>	<b>19,256</b>
<b>Current assets</b>		
Inventories	12,384	9,298
Financial assets		
i. Investments	8,390	12,590
ii. Trade receivables	11,668	8,676
iii. Cash and cash equivalents	15,046	2,870
iv. Bank balances other than (iii) above	4,110	11,091
v. Other financial assets	930	579
Other current assets	3,420	1,421
<b>Total current assets</b>	<b>55,948</b>	<b>46,525</b>
<b>Total assets</b>	<b>79,316</b>	<b>65,781</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	1,323	1,323
Other equity	59,212	51,730
<b>Total equity</b>	<b>60,535</b>	<b>53,053</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
i. Borrowings	1,333	-
ii. Other financial liabilities	344	291
Provisions	741	454
Deferred tax liabilities (Net)	306	-
<b>Total non-current liabilities</b>	<b>2,724</b>	<b>745</b>
<b>Current liabilities</b>		
Financial liabilities		
i. Borrowings	667	-
ii. Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	510	366
(b) total outstanding dues of creditors other than micro enterprises and small enterprises	9,215	7,573
iii. Other financial liabilities	2,044	1,763
Other current liabilities	586	670
Provisions	2,911	1,611
Current tax liabilities (Net)	124	-
<b>Total current liabilities</b>	<b>16,057</b>	<b>11,983</b>
<b>Total liabilities</b>	<b>18,781</b>	<b>12,728</b>
<b>Total equity and liabilities</b>	<b>79,316</b>	<b>65,781</b>

**SIGNED FOR IDENTIFICATION  
BY**  
  
**S R B C & CO LLP  
MUMBAI**



**STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026**

Particulars	Quarter ended			Year ended	
	31-03-2026	31-Dec-25	31-03-2025	31-03-2026	31-03-2025
	Audited	Unaudited	Audited	Audited	Audited
	(Rs. in Lakhs)				
1 Revenue from Operations	17,689	18,003	14,309	70,752	65,343
2 Other Income (Refer note 3(a))	1,240	341	506	2,558	1,268
<b>3 Total Income (1+2)</b>	<b>18,929</b>	<b>18,344</b>	<b>14,815</b>	<b>73,310</b>	<b>66,611</b>
<b>4 Expenses</b>					
(a) Cost of Materials Consumed	3,643	3,479	2,689	13,598	11,026
(b) Purchases of Stock-in-Trade	2,263	4,363	2,122	13,810	9,514
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	153	(1,352)	61	(2,199)	861
(d) Employee Benefits Expense	3,630	3,532	3,160	14,148	12,614
(e) Finance Costs	39	25	18	89	62
(f) Depreciation and Amortisation Expense	574	538	537	2,148	2,143
(g) Other Expenses	4,717	4,005	3,728	16,686	15,363
<b>Total Expenses</b>	<b>15,019</b>	<b>14,590</b>	<b>12,315</b>	<b>58,280</b>	<b>51,583</b>
<b>5 Profit before exceptional items and tax (3-4)</b>	<b>3,910</b>	<b>3,754</b>	<b>2,500</b>	<b>15,030</b>	<b>15,028</b>
6 Exceptional items (net) (Refer Note 3)	110	(842)	10,990	390	8,260
<b>7 Profit before tax</b>	<b>4,020</b>	<b>2,912</b>	<b>13,490</b>	<b>15,420</b>	<b>23,288</b>
<b>8 Income tax expenses</b>					
a. Current Tax	721	691	1,748	3,475	4,969
b. Deferred Tax	309	8	7	428	(5)
<b>Total tax expenses</b>	<b>1,030</b>	<b>699</b>	<b>1,755</b>	<b>3,903</b>	<b>4,964</b>
<b>9 Profit for the period (7-8)</b>	<b>2,990</b>	<b>2,213</b>	<b>11,735</b>	<b>11,517</b>	<b>18,324</b>
<b>10 Other Comprehensive Income</b>					
(i) Items that will not be reclassified to Profit or Loss	10	(91)	(154)	(86)	(147)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	(2)	23	39	22	37
<b>Other Comprehensive Income / (Loss) Net of Tax</b>	<b>8</b>	<b>(68)</b>	<b>(115)</b>	<b>(64)</b>	<b>(110)</b>
<b>11 Total Comprehensive Income for the period (9+10)</b>	<b>2,998</b>	<b>2,145</b>	<b>11,620</b>	<b>11,453</b>	<b>18,214</b>
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323
13 Other Equity				59,212	51,730
14 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):					
(a) Basic (in Rs.)	18.08	13.38	70.96	69.64	110.80
(b) Diluted (in Rs.)	18.08	13.38	70.96	69.64	110.80

**SIGNED FOR IDENTIFICATION**  
BY  
AK  
**S R B C & CO LLP**  
MUMBAI



**Certification pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with the Stock Exchanges, we, the undersigned, Ashok Nair, Managing Director and Amol Lone, Chief Financial Officer of RPG Life Sciences Limited, hereby jointly certify that the enclosed audited Standalone and Consolidated Financial Results for the quarter and year ended on March 31, 2026, do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained in the said financial results misleading.



**Ashok Nair**  
Managing Director

Date: April 29, 2026



**Amol Lone**  
Chief Financial Officer